{"organizations": [], "uuid": "c9b35c8e2e0a8b1b7045edcd44c7e79bc7988b3d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "https://www.reuters.com/finance/personal-finance/analyst-research", "section_title": "Wealth, Personal Finance &amp; Money | Reuters.com", "url": "https://www.reuters.com/article/brief-gw-pharmaceuticals-receives-orphan/brief-gw-pharmaceuticals-receives-orphan-drug-designation-from-ema-for-cannabidiol-for-the-treatment-of-tuberous-sclerosis-idUSFWN1QH0OJ", "country": "US", "domain_rank": 408, "title": "BRIEF-GW Pharmaceuticals Receives Orphan Drug Designation From EMA For Cannabidiol For The Treatment Of Tuberous Sclerosis", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.309, "site_type": "news", "published": "2018-02-27T20:09:00.000+02:00", "replies_count": 0, "uuid": "c9b35c8e2e0a8b1b7045edcd44c7e79bc7988b3d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-gw-pharmaceuticals-receives-orphan/brief-gw-pharmaceuticals-receives-orphan-drug-designation-from-ema-for-cannabidiol-for-the-treatment-of-tuberous-sclerosis-idUSFWN1QH0OJ", "ord_in_thread": 0, "title": "BRIEF-GW Pharmaceuticals Receives Orphan Drug Designation From EMA For Cannabidiol For The Treatment Of Tuberous Sclerosis", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "treatment of tuberous sclerosis", "sentiment": "negative"}, {"name": "gw pharmaceuticals plc", "sentiment": "negative"}, {"name": "gw", "sentiment": "none"}, {"name": "epidiolex", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - GW Pharmaceuticals Plc:\n* GW PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY (EMA) FOR CANNABIDIOL FOR THE TREATMENT OF TUBEROUS SCLEROSIS\n* GW PHARMACEUTICALS PLC - SUBJECT TO POSITIVE RESULTS, GW EXPECTS TO SUBMIT REGULATORY APPLICATIONS IN 2019 FOR EPIDIOLEX IN TS IN BOTH U.S. AND EUROPE Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-27T20:09:00.000+02:00", "crawled": "2018-02-27T14:11:58.073+02:00", "highlightTitle": ""}